Glaukos reported a second-quarter 2026 adjusted loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 28 cents, and revenues of $185.6 million, up 50% year over year, surpassing estimates by 24.1%. The company raised its 2026 revenue guidance to $680 million to $700 million, up from the previous $620 million to $635 million, driven by strong adoption of iDose TR and the Epioxa launch. U.S. Glaucoma revenues hit a record $118.5 million, up 64%, while International Glaucoma revenues rose 17% to $36.6 million, and Corneal Health revenues increased 48% to $30.4 million. Adjusted gross margin expanded to 84.5%, and the company exited the quarter with $286.2 million in cash and no debt. Shares have gained about 8% since the earnings report, outperforming the S&P 500, and the consensus estimate has shifted upward by 25.93% over the past month.
Glaukos CorpBeat Q2 estimates and raised 2026 revenue guidance, driving positive earnings revision.
Thermo Fisher Scientific Inc